Q-omics provides the consensus-scored RPS27L profile across patient tissues and cancer cell-line models. RPS27L expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in UCEC. Among the 18 cancer types available for tumor–normal comparison, RPS27L is differentially expressed in 11, with the highest sampling consensus in KIRC. Additionally, RPS27L protein abundance shows 20,972 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight UCEC, KIRC, and LSCC as cancer lineages where RPS27L shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RPS27L — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RPS27L survival associations across molecular data types. RPS27L RNA expression shows survival associations in the most cancer types (24), followed by mutation status (5) and mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RPS27L RNA expression–survival associations across cancer types. High RPS27L expression shows unfavorable associations in UCS, MESO and SCLC, but favorable associations in UCEC, LIHC and THCA. The UCEC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify UCEC as the clearest survival context for RPS27L RNA expression.
This table summarizes RPS27L tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11, while mass-spec protein shows differences in 4. The strongest signals are observed in KIRC for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for RPS27L. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RPS27L shows lower tumor expression in LUSC and KICH and higher tumor expression in KIRC, THCA, LIHC and CHOL. The KIRC box plot shows higher RPS27L RNA expression in tumor versus normal tissue (log2 FC = +0.745, t-test p < 0.001).
This table shows molecular features associated with RPS27L in patient tissues and cancer cell lines. In patient samples, RPS27L shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, RPS27L RNA and mutation anchors are most strongly linked to RNA-expression features, especially in PANCREAS, while CRISPR and shRNA rows add functional-dependency signals in BONE and BLOOD_Leukemia.
